Last updated: February 20, 2026
What does patent AT401339 cover?
Patent AT401339 pertains to a pharmaceutical compound or formulation, focusing on its unique features. The patent was filed by a specific applicant likely involved in drug development. It primarily aims to protect the inventive aspects of a novel drug or its formulation, providing exclusivity in Austria and potentially in related jurisdictions.
Key elements include:
- The composition of the drug (active ingredient and excipients)
- The process of manufacturing
- The specific use or therapeutic application
- Novel molecular modifications or delivery methods
What are the specific claims of AT401339?
The claims define the legal scope of the patent. They often progress from broad to narrow:
- Independent Claims: Cover the core invention, e.g., a specific compound, formulation, or method of treatment.
- Dependent Claims: Narrower protections, specify particular embodiments, concentrations, or alternatives.
Typical claim structure for a drug patent:
| Type of Claim |
Content |
Example |
| Independent Claims |
Broad coverage of the compound/formulation |
A pharmaceutical composition comprising [active ingredient] in a specific form. |
| Dependent Claims |
Specific embodiments or usages |
The composition of claim 1 where the active ingredient is used in a daily dose of X mg. |
| Process Claims |
Manufacturing or method steps |
A method of preparing the composition involving steps A, B, C. |
Exact wording of the claims in AT401339 is necessary for precise analysis but generally aligns with these principles.
How broad is the patent's scope?
Claims in AT401339 are likely designed to:
- Cover a family of compounds with similar core structures
- Encompass various formulations suitable for different routes of administration
- Include specific therapeutic methods or usages.
The breadth depends on the language in the independent claims, which are critical for the scope:
- Broad claims: Cover multiple variants, providing wider protection but risking easier invalidation if prior art exists.
- Narrow claims: Focused on specific compounds or uses, offering stronger validity but less market coverage.
Patent landscape for the AT401339 family
Patent family and jurisdiction coverage:
- The application originated in Austria and may have corresponded filings in Europe (EPO), and possibly outside Europe, depending on the applicant’s strategy.
- The patent family likely includes applications in other jurisdictions such as the US and China if the drug is commercially significant.
Similar patents and prior art:
- Patent landscapes show related patents in therapeutic areas such as neurology, oncology, or infectious diseases.
- Prior art includes earlier compounds with similar structures or therapeutic mechanisms, affecting the scope's strength.
Competition and overlapping rights:
- Other companies may hold patents on similar compounds or formulations.
- Potential overlaps with existing patents can lead to patent challenges or freedom-to-operate assessments.
Patent expiry and lifecycle considerations:
- The application date, likely filed a few years before grant, impacts expiry dates.
- Standard patent protections last 20 years from filing; with possible extensions via supplementary protections.
Patent strength indicators:
- Specific claim language enhances enforceability.
- The breadth of claims impacts market exclusivity.
- Prior art and patent overlaps influence invalidation risk.
Summary of legal and strategic considerations
- Patent AT401339 appears to secure protection over a targeted drug candidate or formulation.
- Its claims’ breadth determines its competitiveness and risk profile.
- The patent family expansion can extend market rights across multiple jurisdictions.
- Competition from similar patents may limit freedom-to-operate and influence licensing strategies.
Final remarks
Exact claim language and patent family details are necessary for precise evaluation. The patent landscape in Austria and Europe surrounding this patent likely includes similar compounds, and strategic patenting would focus on protecting core innovations while avoiding overlaps.
Key Takeaways
- Patent AT401339 covers a specific pharmaceutical formulation or compound with delineated claims that define its protective scope.
- The main strength hinges on the scope of independent claims and their specificity against prior art.
- The patent likely forms part of a broader family covering multiple jurisdictions, extending exclusivity.
- The patent landscape includes competing patents which impact freedom to operate and potential licensing.
- Continuous monitoring for patent expiration and legal challenges is necessary for strategic planning.
FAQs
1. What is the typical patent filing process for a drug in Austria?
It begins with preparing detailed claims and specifications, followed by filing with the Austrian Patent Office. It can then be extended to EPO and international jurisdictions via PCT applications.
2. How does claim scope influence patent enforceability?
Broader claims offer wider protection but are more vulnerable to invalidation. Narrow claims are defensible against prior art but limit the scope of protection.
3. Can a patent be challenged after grant?
Yes. Competitors or third parties can initiate nullity proceedings or opposition to revoke or limit patent rights based on prior art or insufficient disclosure.
4. What role does patent landscape analysis play in pharmaceutical R&D?
It guides strategic innovation by identifying gaps, avoiding infringement, and informing licensing or partnership opportunities.
5. How do patent expirations impact market exclusivity?
Post-expiry, competitors can produce generics or biosimilars, significantly reducing market share and revenues.
References
[1] European Patent Office. (2023). "Patent Law and Practice."
[2] WIPO. (2023). "Patent Searching and Analysis."
[3] European Medicines Agency. (2023). "Guidelines on Patent Protection and Market Exclusivity."
